Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson’s disease ; day:2 ; month:9 ; year:2022 ; pages:1-11
Journal of neurology ; (2.9.2022), 1-11
- Creator
-
Waggan, Imran
Rissanen, Eero
Tuisku, Jouni
Joutsa, Juho
Helin, Semi
Parkkola, Riitta
Rinne, Juha O.
Airas, Laura
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-022-11342-1
- URN
-
urn:nbn:de:101:1-2022112009284194485584
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Waggan, Imran
- Rissanen, Eero
- Tuisku, Jouni
- Joutsa, Juho
- Helin, Semi
- Parkkola, Riitta
- Rinne, Juha O.
- Airas, Laura
- SpringerLink (Online service)
Other Objects (12)
Adenosine A2A receptors in Parkinson’s disease treatment
Increased ATP Release and Higher Impact of Adenosine A2A Receptors on Corticostriatal Plasticity in a Rat Model of Presymptomatic Parkinson’s Disease
Adenosin A2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment
A2A adenosine receptor interacting partners (interactome)
The mGlu5 Receptor Protomer-Mediated Dopamine D2 Receptor Trans-Inhibition Is Dependent on the Adenosine A2A Receptor Protomer: Implications for Parkinson’s Disease
Histamine H3 receptor antagonists in combination with monoamine oxidase B and adenosine A1/A2A receptor ligands as multi-target approach for the treatment of Parkinson´s disease
VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder
Inhibition by adenosine A2A receptors of NMDA and GABAA receptor-mediated synaptic transmission in a subpopulation of rat striatal neurons : an aspect of adenosine effects in Parkinson's disease
A covalent antagonist for the human adenosine A2A receptor
Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment
Positive allosteric modulation of the adenosine A2a receptor attenuates inflammation
Adenosine A2A receptors in Parkinson’s disease treatment
Increased ATP Release and Higher Impact of Adenosine A2A Receptors on Corticostriatal Plasticity in a Rat Model of Presymptomatic Parkinson’s Disease
Adenosin A2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment
A2A adenosine receptor interacting partners (interactome)
The mGlu5 Receptor Protomer-Mediated Dopamine D2 Receptor Trans-Inhibition Is Dependent on the Adenosine A2A Receptor Protomer: Implications for Parkinson’s Disease
Histamine H3 receptor antagonists in combination with monoamine oxidase B and adenosine A1/A2A receptor ligands as multi-target approach for the treatment of Parkinson´s disease
VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder
Inhibition by adenosine A2A receptors of NMDA and GABAA receptor-mediated synaptic transmission in a subpopulation of rat striatal neurons : an aspect of adenosine effects in Parkinson's disease
A covalent antagonist for the human adenosine A2A receptor
Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment
Positive allosteric modulation of the adenosine A2a receptor attenuates inflammation
Adenosine A2A receptors in Parkinson’s disease treatment
Increased ATP Release and Higher Impact of Adenosine A2A Receptors on Corticostriatal Plasticity in a Rat Model of Presymptomatic Parkinson’s Disease
Adenosin A2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment
A2A adenosine receptor interacting partners (interactome)
The mGlu5 Receptor Protomer-Mediated Dopamine D2 Receptor Trans-Inhibition Is Dependent on the Adenosine A2A Receptor Protomer: Implications for Parkinson’s Disease
Histamine H3 receptor antagonists in combination with monoamine oxidase B and adenosine A1/A2A receptor ligands as multi-target approach for the treatment of Parkinson´s disease
VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder
Inhibition by adenosine A2A receptors of NMDA and GABAA receptor-mediated synaptic transmission in a subpopulation of rat striatal neurons : an aspect of adenosine effects in Parkinson's disease
A covalent antagonist for the human adenosine A2A receptor
Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment